Would you use trastuzumab with chemotherapy in a patient with metastatic gastric cancer that is HER2 negative but ERBB3 positive?

No, there are clearly no validated data for this and I do not have any anecdotal experience to suggest benefit.

Such a patient should be referred for studies of pan-ErBB inhibitors, e.g. afatinib or neratinib.